drugset / Trial / NCT05752526

A Study of Diclofenac Gel in Women With Primary Dysmenorrhea

NCT05752526

Phase 1 Completed 42 enrolled Daré Bioscience, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this clinical trial is to compare 1% and 3% diclofenac gel (DARE-PDM1) to placebo in women with symptomatic primary dysmenorrhea. The main question it aims to answer are: Is DARE-PDM1 1%, 3% diclofenac gel systemically safe? What are the systemic levels of DARE-PDM1 1%, 3% diclofenac gel in plasma and vaginal fluid following 1 dose and 3 doses. Participants will be seen for routine safety evaluations and complete a daily diary recording dysmenorrhea associated pain.

Timeline

Start
2023-05-19
Primary completion
2023-10-10
Completion
2024-04-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Diclofenac Other / unclassified 1 % Other
Subject Diclofenac Other / unclassified 3 % Other

Indications